Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Monday, November 03, 2025
Sharp Services announced a $100M investment across its global facility network to address increasing market demand for established and new medicines.
read more
Thursday, October 30, 2025
Piramal Pharma announced its strategic partnership with Korean biotech firm IntoCell to expand its offerings in the rapidly growing antibody-drug conjugate (ADC) and bioconjugate market.
read more
Thursday, October 30, 2025
WuXi AppTec has reached a definitive agreement to sell its China-based clinical research services subsidiaries, WuXi Clinical and WuXi MedKey, to Hillhouse Investment Management, a global private asset manager.
read more
Simtra BioPharma Solutions is making progress on a dual-continent expansion strategy to meet growing global demand for complex, high-value therapies. Since becoming an independent company in 2023, Simtra has accelerated its growth across North ...
read more
Curia Global announced the completion of a $4M investment to upgrade its two API aseptic suites in Valladolid, Spain.
read more
SK pharmteco has announced a $6.1M investment in its Rancho Cordova, California site to expand and equip a new laboratory and CGMP facility dedicated to kilogram-scale solid-phase peptide synthesis (SPPS) and purification operations.
read more
OWP Pharmaceuticals has chosen EVERSANA to provide commercialization support for the U.S. launch of SUBVENITE® (lamotrigine) oral suspension, a recently FDA-approved treatment for epilepsy and bipolar disorders.
read more
Kindeva announced the promotion of David Stevens, Chief Operating and Commercial Officer, to the newly created role of President. In this capacity, David will lead Kindeva’s global operations.
read more
Thursday, October 23, 2025
Samsung Biologics announced a shareholder-approved split of its business divisions, positioning itself as a pure-play contract development and manufacturing organization (CDMO). The move, passed with 99.9% approval at an extraordinary shareholders’ ...
read more
Thursday, October 23, 2025
AGC Biologics has entered into an agreement with Rarity PBC to develop and manufacture RDP-101, a breakthrough gene therapy targeting Adenosine Deaminase Severe Combined Immunodeficiency Disorder (ADA-SCID), also known as “Bubble Baby Disease”.
read more
Thursday, October 23, 2025
Aenova announced a major investment in its sterile manufacturing capabilities with the installation of another fill & finish (F&F) line at its Latina site. This expansion marks a significant step in meeting the growing global demand for biologics ...
read more
Wednesday, October 22, 2025
Cambrex announced a $120 million investment aimed at expanding active pharmaceutical ingredient (API) manufacturing capacity in the United States, reinforcing domestic supply chain resilience and supporting the growing peptide therapeutics segment.
read more
Wednesday, October 22, 2025
Serán BioScience has announced an expansion of its commercial manufacturing footprint with the development of a new 100,000-square-foot campus in Bend, Oregon.
read more
Tuesday, October 21, 2025
Upperton Pharma Solutions has expanded its GMP manufacturing capabilities with the installation of a Fill2Weight gravimetric powder filling system from 3P innovation at its 60,000-square-foot facility in Nottingham, UK.
read more
Tuesday, October 21, 2025
Ajinomoto Bio-Pharma Services and Gene Tools have announced a collaboration to expand access to phosphorodiamidate morpholino oligomer (PMO) therapeutics, a growing class of oligonucleotide drugs that show promise in treating genetic diseases such as...
read more